1224 related articles for article (PubMed ID: 18772033)
21. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
Amargós-Bosch M; Adell A; Artigas F
J Neurochem; 2007 Jul; 102(2):550-61. PubMed ID: 17394545
[TBL] [Abstract][Full Text] [Related]
22. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
Huang M; Horiguchi M; Felix AR; Meltzer HY
Neuroreport; 2012 May; 23(7):436-40. PubMed ID: 22415605
[TBL] [Abstract][Full Text] [Related]
23. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
24. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
Saller CF; Czupryna MJ; Salama AI
J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636
[TBL] [Abstract][Full Text] [Related]
25. Serotonin and dopamine interactions in psychosis prevention.
Richtand NM; McNamara RK
Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
[TBL] [Abstract][Full Text] [Related]
26. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism.
Chung YC; Li Z; Dai J; Meltzer HY; Ichikawa J
Brain Res; 2004 Oct; 1023(1):54-63. PubMed ID: 15364019
[TBL] [Abstract][Full Text] [Related]
27. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
28. Role of serotonin in the action of atypical antipsychotic drugs.
Meltzer HY
Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
[TBL] [Abstract][Full Text] [Related]
29. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
[TBL] [Abstract][Full Text] [Related]
30. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
Rauser L; Savage JE; Meltzer HY; Roth BL
J Pharmacol Exp Ther; 2001 Oct; 299(1):83-9. PubMed ID: 11561066
[TBL] [Abstract][Full Text] [Related]
31. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.
López-Gil X; Artigas F; Adell A
Curr Pharm Des; 2010; 16(5):502-15. PubMed ID: 19909228
[TBL] [Abstract][Full Text] [Related]
32. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
Di Pietro NC; Seamans JK
Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
[TBL] [Abstract][Full Text] [Related]
33. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
34. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
Marek GJ
Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
[TBL] [Abstract][Full Text] [Related]
35. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release.
Ichikawa J; Chung YC; Dai J; Meltzer HY
Brain Res; 2005 Aug; 1052(1):56-62. PubMed ID: 16061211
[TBL] [Abstract][Full Text] [Related]
36. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
37. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Prog Brain Res; 2008; 172():287-305. PubMed ID: 18772038
[TBL] [Abstract][Full Text] [Related]
38. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats.
Horiguchi M; Huang M; Meltzer HY
J Pharmacol Exp Ther; 2011 Aug; 338(2):605-14. PubMed ID: 21558435
[TBL] [Abstract][Full Text] [Related]
39. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
40. Alterations of dopamine and serotonin transmission in schizophrenia.
Remington G
Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
